Leede Financial Expects Lower Earnings for Theratechnologies

Theratechnologies Inc. (TSE:TH - Free Report) - Stock analysts at Leede Financial decreased their FY2025 EPS estimates for Theratechnologies in a report released on Monday, April 14th. Leede Financial analyst D. Loe now expects that the company will post earnings per share of ($0.27) for the year, down from their previous forecast of $0.09. The consensus estimate for Theratechnologies' current full-year earnings is $0.03 per share.

A number of other brokerages also recently issued reports on TH. Research Capitl upgraded Theratechnologies to a "strong-buy" rating in a research report on Friday, February 14th. Jones Trading raised shares of Theratechnologies from a "hold" rating to a "strong-buy" rating in a report on Friday, April 11th.

Theratechnologies Stock Performance

Shares of TH stock remained flat at C$3.48 during trading hours on Wednesday. 39,206 shares of the stock were exchanged, compared to its average volume of 102,941. The stock has a 50 day simple moving average of C$2.44 and a two-hundred day simple moving average of C$2.21. The firm has a market capitalization of C$111.03 million, a price-to-earnings ratio of -39.39, a PEG ratio of -8.50 and a beta of 1.73. Theratechnologies has a one year low of C$1.59 and a one year high of C$4.33. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of -293.92.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.